In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

The meeting, held between November 29 and December 2 in Barcelona, brought together experts and opinion leaders in the field of multiple sclerosis from around the world.

The grant program offers young researchers the opportunity to further their training in the field of multiple sclerosis.

The award recognizes people with an outstanding career for their relationship with the University and their social impact.

The list identifies the most influential experts, who are among the 1% most cited in their speciality in several areas of knowledge.

The award is a recognition for his significant contribution to the development of research in multiple sclerosis within the Catalan Institute of Health.

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

The ability to be able to diagnose and differentiate both diseases as early as possible is fundamental to impact and stop the evolution of the disease before irreversible damage occurs.

The results of the study show for the first time that patients who start treatment less than six months after having the first symptoms of the disease have a slower progression and less disability than when therapy is started more than 16 months later.

This is the most prestigious international award in the multiple sclerosis scientific and social community, given in recognition of life-long work in care, research and teaching in relation to the disease.

The finding opens the door to the development of new therapies that block neurodegeneration, beyond current treatments that focus on the inflammatory process and the control of relapses.

Research has found that a significant number of patients with the Relapsing-Remitting variant have Progression Independent of Relapse Activity episodes.

A Vall d'Hebron study has identified this new marker, visible at the time of diagnosis, which can serve as a guide for both patients and professionals.

Els doctors Xavier Montalban, Àlex Rovira i Mar Tintoré han estat reconeguts en la categoria de Neurociències i Comportament, i el doctor Jordi Rello en la categoria Interdisciplinària.

The research led by Vall d'Hebron is a breakthrough in the search for specific and effective treatments for the disease.

The study conducted at Vall d'Hebron shows that having a high level of neurofilament light chains translates, over the years, to a higher level of disability.

The research aims to identify which patients with isolated radiological syndrome are more likely to develop the disease.

El premi reconeix les contribucions més destacades a nivell mundial a la investigació en la comprensió, el tractament o la prevenció de l'esclerosi múltiple.

Among the 108 Spanish scientists recognised on the 2021 Web of Science Group list, two from Vall d’Hebron Research Institute stand out: Dr Maria Buti and Dr Xavier Montalban.

El cap del Servei de Neurologia-Neuroimmunologia Clínica de l’Hospital Vall d’Hebron, cap del Grup d’Investigació en Neuroimmunologia Clínica del VHIR i director del Centre d'Esclerosi Múltiple de Catalunya (Cemcat) ha liderat el comitè d’elaboració de la guia europea amb recomanacions per a neuròlegs i pacients, basades en l’evidència existent, sobre l’eficàcia de tractaments, que ha presentat al Congrés del Comitè Europeu del Tractament i Recerca en Esclerosi Múltiple (ECTRIMS).

La Dra. Carmen Tur rebrà un ajut per al projecte “Caracterització de patrons espai temporals de dany tissular cerebral en esclerosi múltiple mitjançant tècniques d'aprenentatge profund no supervisat”.